AI주식인사이트AI Stock Insight
B

츌립앤사이언스

291650KOSDAQ

56.0 / 100

Reference Date: 2026-10-23

Financial Score17.5 / 40
News Sentiment12.5 / 25
Momentum16.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 52.7% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

AptaMera Science is a biotech company spun off from POSTECH in 2011, specializing in the development of innovative therapeutics based on aptamer technology and offering CRO services for biopharmaceutical analysis. Utilizing its proprietary ApDC® platform, the company is advancing the development of targeted anti-cancer drugs for solid and hematologic malignancies, with key candidates like AST-201 and AST-202 in clinical trials, and expanded into CRO services in 2024.

Number of Employees

44people

Average Salary

54.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
2.70Industry Average 1.200.0Point

2.3x industry avg (risky)

ROE
-32.13Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
3.91Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲284.5% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲15.8% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -45.2% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position8.0Point

Near 52w high (84%, uptrend)

Current 2,500Won52-week high 2,83552-week low 684
1-month return6.0Point

1m +52.72% (strong rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0